MDT-AP-1135
Med · Medulloblastoma
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- Med
- cancer_type_detailed
- —
- subtype
- Medulloblastoma
- cancer_type
- Med
- subtype
- Medulloblastoma
- overall_survival_months
- 23.04
- os_event
- false
- age_years
- 12
- sex
- F
- new_clusters
- C3
- umap1_2d
- 6.004058235
- umap2_2d
- 2.858658667
- umap1_3d
- 2.822709247
- umap2_3d
- -3.029995349
- umap3_3d
- -2.210824793
- dataset
- Med-Taylor
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- KRAS_SIGNALING_DN+0.200
- WNT_BETA_CATENIN_SIGNALING+0.200
- MITOTIC_SPINDLE+0.130
- HYPOXIA+0.120
- HEME_METABOLISM+0.110
- MYOGENESIS+0.080
- PANCREAS_BETA_CELLS+0.070
- SPERMATOGENESIS+0.070
- ANGIOGENESIS+0.030
- APICAL_JUNCTION+0.030
Top 10 suppressed
- MYC_TARGETS_V1-0.500
- INTERFERON_ALPHA_RESPONSE-0.440
- ANDROGEN_RESPONSE-0.430
- INTERFERON_GAMMA_RESPONSE-0.410
- OXIDATIVE_PHOSPHORYLATION-0.380
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.360
- PROTEIN_SECRETION-0.350
- INFLAMMATORY_RESPONSE-0.330
- MTORC1_SIGNALING-0.330
- ALLOGRAFT_REJECTION-0.300
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
7 twins match this tumor's tissue · 3 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | MDT-AP-0222 | Med | Medulloblastoma | 0.864 |
| 2 | MNG1257 | — | — | 0.850 |
| 3 | MDT-AP-1160 | Med | Medulloblastoma | 0.849 |
| 4 | MDT-AP-1261 | Med | Medulloblastoma | 0.846 |
| 5 | MDT-AP-0179 | Med | Medulloblastoma | 0.846 |
| 6 | SRR1404168 | GTEX | — | 0.844 |
| 7 | SRR4195662 | — | — | 0.841 |
| 8 | BS_9CA93S6D | Diffuse intrinsic pontine glioma | — | 0.840 |
| 9 | TCGA-90-A4ED-01A-31R-A24Z-07 | — | cohortMD1 | 0.839 |
| 10 | SRR1379562 | GTEX | — | 0.837 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 11 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| KRAS_SIGNALING_DN | 0.200 | Remibrutinib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.200 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.130 | Inavolisib | — uncovered |
| HYPOXIA | 0.120 | Idelalisib | — uncovered |
| HEME_METABOLISM | 0.110 | Temsirolimus | — uncovered |
| MYOGENESIS | 0.080 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.070 | Cobimetinib | — uncovered |
| SPERMATOGENESIS | 0.070 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.030 | Remibrutinib | — uncovered |
| APICAL_JUNCTION | 0.030 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.010 | Inavolisib | — uncovered |